GeneCentric
PrivateLast Round
Series C
Jun 18, 2025
Total Funding Raised
$28.25M
Company Overview
GeneCentric is a precision oncology company that develops AI-driven diagnostic solutions and RNA-based gene expression signatures to identify patient populations likely to respond to specific cancer therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GeneCentric Comparables
Compare GeneCentric with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cofactor Genomics | 82% | |
| Exai Bio | 76% | |
| Labcorp | 74% |
GeneCentric Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 18, 2025 | ||||
| Series B Extension | Nov 8, 2021 | ||||
| Series B | Sep 22, 2021 | ||||
| VC Round | Dec 22, 2016 | ||||
| Series A | Jul 22, 2014 | ||||
VC Round | Jul 8, 2013 |
Key People
Founding team and executive leadership
GeneCentric Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IAG Capital Partners | Series B Extension, Series B, Series C |
| Hatteras Venture Partners | Series A, Series B Extension, Series B, VC Round, Series C, Seed |
| Alexandria Venture Investments | Series B, Series C |
| Alexandria Venture Investments | Series B Extension, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 9, 2025
Launched PurIST, an RNA-based tumor classification test, with Tempus.
- Sep 9, 2025
Collaborated with Tempus to develop and deploy PurIST RNA-based algorithm test.
Recent news
Latest coverage and updates
- launchesJul 8, 2026
GeneCentric Diagnostics, Inc. launched ExpressCT Rewind on Jul 8th '26.
GeneCentric Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about GeneCentric's valuation, stock price, and market status.
Is GeneCentric a public or private company?
GeneCentric is a private company.
What is the current stock price of GeneCentric?
GeneCentric is a private company with no public stock price. No recent secondary market data is available.
How much is GeneCentric worth (valuation)?
Valuation information for GeneCentric is not publicly available.
Can I buy GeneCentric stock?
GeneCentric shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was GeneCentric's last funding round?
GeneCentric's most recent funding round was Series C on June 18, 2025.
Who are the main investors in GeneCentric?
Key investors in GeneCentric include Hatteras Venture Partners.
Will GeneCentric IPO soon?
No public IPO plans have been announced for GeneCentric.
How can I track GeneCentric secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor GeneCentric's secondary market activity and sign up for updates.